DOCSLIB.ORG

Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed As

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed As Pediatric Reports 2011; volume 3:e19 Neuroleptic malignant of adrenoceptors may further increase pre- frontal cortical activity and could enhance Correspondence: Ali Ertug Arslankoylu, Mersin syndrome due to risperidone antipsychotic efficacy by modulations of University Faculty of Medicine, Department of misdiagnosed as status mesolimbic DA activity. Unlike other atypical Pediatrics, Pediatric Intensive Care Unit. 33079, epilepticus agents, risperidone does not differ from con- Mersin, Turkey. ventional agents in its dissociation contrast for Tel. +90.324.3374300.1161 - Fax: +90.324 3374305. E-mail: [email protected] Ali Ertug Arslankoylu, Meryem Ozlem D2 receptor; this feature perhaps accounts for the risk of EPS (extrapyramidal side effects) at Kutuk, Cetin Okuyaz, Fevziye Toros Key words: neuroleptic malignant syndrome, high doses.4 However in large multicentre risperidone, status epilepticus. Mersin University Faculty of Medicine, studies it was shown that risperidone had sim- Department of Pediatrics, Pediatric ilar side effects like other typical neuroleptic Contributions: AEA, manuscript preparation Intensive Care Unit, Mersin, Turkey agents.5 As far as we know the number of cases supervision; MOK, data conception and design; due to risperidone treatment in the literature CO, FT, manuscript revision; AEA,MOK, CO, FT, is limited and most of the reported cases are final manuscript approval. adults. In most of these cases risperidone Abstract induces NMS after two weeks of treatment.6 Received for publication: 27 May 2011. Here we report a child with NMS due to Accepted for publication: 21 June 2011. Neuroleptic malignant syndrome (NMS) is a risperidone treatment who was misdiagnosed This work is licensed under a Creative Commons rare but potentially fatal disease characterized as status epilepticus. The patient reported Attribution NonCommercial 3.0 License (CC BY- by fever, muscle rigidity, delirium and autonom- here met DSM-IV criteria for NMS.1 NC 3.0). ic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status ©Copyright A.E. Arslankoylu et al., 2011 epilepticus. Nine year old boy, who had been Licensee PAGEPress, Italy under high dose risperidone treatment for 8 Case Report Pediatric Reports 2011; 3:e19 doi:10.4081/pr.2011.e19 weeks, admitted to the emergency room because of the contractions (evaluated as status Nine years old boy was admitted to the only epilepticus) persisting for 7 hours. Since there emergency department because of the convul- was neuroleptic treatment in the past medical sions persisting for seven hours. He had atten- EEG were unremarkable. history and, unconsciousness, muscular rigidi- tion deficit hyperactivity disorder and he had Although the tremors accompany muscular ty, diaphoresis, hypertermi and, hypotension in been under risperidone (2¥2 mg/day)use treat- rigidity were mimicking convulsions and the physical examination, leucocytosis and elevated ment orally for 8 weeks because of moderate patient was admitted with staus epilepticus creatininphosphokinase levels in laboratory mental retardation and psychological disorder. diagnosis, the patient was not diagnosed as tests, the patient was evaluated as NMS and dis- Risperidone dose was four times more than status epilepticus because there were neu- charged without any complications. We reported usually recommended pediatric dosage. roleptic treatment in his medical history, mus- this case to point out that; NMS may be misdi- Additionally the patient had been suffering cular rigidity, diaphoresis, hypertermi and agnosed as status epilepticus in children when vomiting, tremor and fever for two weeks. hypotension in physical examination, leucocy- EEG monitoring is unavailable. When a child Physical examination in the emergency tosis and elevated CPK levels in laboratory admitted to the emergency room because of room revealed a body temperature of 39°C, a tests. By the help of the sign and symptoms suspicious convulsion neuroleptic drug use respiratory rate of 10 breaths/min, and, a pulse above, the patient was diagnosed as NMS by must surely be asked. rate of 158 beats/min. Blood pressure was too pediatric critical care intensivist, pediatric low that it couldn’t be measured initially. The neurologist and pediatric psychiatrist. NMS patient’s general appearance was lethargic. diagnosis was confirmed with EEG and risperi- There was muscular rigidity, tremor and, done treatment was ceased. Introduction diaphoresis. He was dehydrated. Heart sounds In the emergency department the patient were rhythmic and tachycardic. His respiration was entubated because of respiratory failure. Neuroleptic malignant syndrome (NMS) is a was weak and respiratory sounds were normal. Then he was admitted to the pediatric inten- rare but potentially fatal disease Non-commercialcharacterized Bilateral pupil reflexes were positive. Deep sive care unit and mechanically ventilated. by fever, muscular rigidity, delirium and auto- tendon reflexes were brisk and bilateral Intravenous diazepam infusion (0.3 mg/kg nomic instability.1 Yearly prevalence of the dis- Babinski reflexes were positive. There were no hour) and carbidopa/levodopa were given for ease in patients under neuroleptic treatment meningeal irritation signs. NMS treatment. In the first day of the admis- ranges between 0.02% and 2.4%. Mortality rate Initial laboratory analysis revealed a white sion to the intensive care unit the patient had of the patients without specific treatment is blood cell count of 21580 cells/mm3, with 2% hyperthermia resistant to the antipyretic treat- approximately 21%.2,3 Mortality rate may be band neutrophils, 62% neutrophils, 30% lym- ment and his blood pressure was unstable. higher in patiens with misdiagnosis like our phocytes, 6% monocytes. Serum electrolytes Central venous catheter was placed and hemo- patient. The classic presentation of this syn- were in normal ranges included a sodium level dynamic parameters of the patient were regu- drome has been most commonly associated of 136 mEq/L; potassium, 5.4 mEq/L; chloride lated in normal ranges. In the second day of with the typical neuroleptic drugs such as 105 mEq/L and, calcium 8.2 mEq/L. The blood the admission to the intensive care unit the haloperidol.2 glucose was 316 mg/dl. Initial venous blood patient was extubated. All the clinical and lab- Risperidone is a new atypical neuroleptic gases showed a pH of 7.04; carbon dioxide ten- oratory signs and symptoms of the patient agent. 5-HT2A antagonism partially protects sion 95 mmHg; bicarbonate 26 mEq/L and, base improved except elevated creatinin phosphoki- against D2 antagonist-induced-neurologic side excess, -5.8 mmol/L. The serum creatinine nase levels which turned back to normal values effects and, may improve negative symptoms phosphokinase (CPK) level was 1658 U/L. on the fifth day of the admission. Then he was and cognitive functioning via modulation of Blood, urine and stool cultures were negative. discharged from the hospital without compli- mesocortical DA activity. In addition, blockade Urinalysis, chest radiograph, cranial CT and cations. [Pediatric Reports 2011; 3:e19] [page 81] Case Report with dopamine. 2. Leibold J, Patel V, Hasan RA. Neuroleptic Discussion Previously it was thought that NMS was only malignant syndrome associated with associated with the use of classical neurolep- ziprasidone in an adolescent. Clin Ther Here we report a patient with NMS who was tics. However there are some NMS cases due 2004;26:1105-8. misdiagnosed as status epilepticus before to atypical neuroleptics in the literature.7 As 3. Steingard R, Khan A, Gonzales A, Herzog admission to our hospital. Our patient was far as we know in the literature only two NMS D. Neuroleptic malignant syndrome: diagnosed as NMS due to presence of men- cases due to risperidone treatment were review of experience with children and tioned criteria of NMS.1 Mortality rate of NMS reported in children.8,9 We think that atypical adolescents. J Child Adolesc Psychophar - in the patients without specific treatment is neuroleptics will be extensively used in chil- macol 1992;2:183-98. approximately 21%.2,3 Mortality rate may be dren in the future and the clinicians especial- 4. Gertz HJ, Schmidt LG. Low melatonin con- higher in patiens with misdiagnosis. NMS ly the pediatricians must be familiar to NMS tent of substantia nigra in a case of neu- signs and symptoms may be difficult to differ- and its differential diagnosis. roleptic malignant syndrome. Pharmaco - entiate from status epilepticus by inexperi- We report this case in order to underline psychiatry 1991;24:93-5. enced physicians when EEG monitoring is that neuroleptic malignant syndrome may be 5. Ballard C, Grace J, Mckeith J, Holmes C. unavailable. As mentioned before, our patient misdiagnosed as status epilepticus in children Neuroleptic sensitivity in dementia with was diagnosed as status epilepticus before he when EEG monitoring is unavailable. When a Lewy bodies and Alzheimer’s disease. was admitted to our hospital and he had been child is admitted to the emergency department Lancet 1998;351:1032. tried to be treated as status epilepticus at the because of unconsciouesness muscular rigidi- 6. Caroff SN, Mann SC. Neuroleptic malig- beginning. ty, diaphoresis, hypertermi and hypotension; nant syndrome. Med Clin North Am 1993; The clinical signs and symptoms of our neuroleptic drug use must surely be asked. 77:185-202. patient emerged in the second week of the Furthermore this is the third neuroleptic
Load more

Recommended publications
  • Status Epilepticus Clinical Pathway
    JOHNS HOPKINS ALL CHILDREN’S HOSPITAL Status Epilepticus Clinical Pathway 1 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Table of Contents 1. Rationale 2. Background 3. Diagnosis 4. Labs 5. Radiologic Studies 6. General Management 7. Status Epilepticus Pathway 8. Pharmacologic Management 9. Therapeutic Drug Monitoring 10. Inpatient Status Admission Criteria a. Admission Pathway 11. Outcome Measures 12. References Last updated: July 7, 2019 Owners: Danielle Hirsch, MD, Emergency Medicine; Jennifer Avallone, DO, Neurology This pathway is intended as a guide for physicians, physician assistants, nurse practitioners and other healthcare providers. It should be adapted to the care of specific patient based on the patient’s individualized circumstances and the practitioner’s professional judgment. 2 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Rationale This clinical pathway was developed by a consensus group of JHACH neurologists/epileptologists, emergency physicians, advanced practice providers, hospitalists, intensivists, nurses, and pharmacists to standardize the management of children treated for status epilepticus. The following clinical issues are addressed: ● When to evaluate for status epilepticus ● When to consider admission for further evaluation and treatment of status epilepticus ● When to consult Neurology, Hospitalists, or Critical Care Team for further management of status epilepticus ● When to obtain further neuroimaging for status epilepticus ● What ongoing therapy patients should receive for status epilepticus Background: Status epilepticus (SE) is the most common neurological emergency in children1 and has the potential to cause substantial morbidity and mortality. Incidence among children ranges from 17 to 23 per 100,000 annually.2 Prevalence is highest in pediatric patients from zero to four years of age.3 Ng3 acknowledges the most current definition of SE as a continuous seizure lasting more than five minutes or two or more distinct seizures without regaining awareness in between.
    [Show full text]
  • The Migraine-Epilepsy Syndrome
    medigraphic Artemisaen línea Arch Neurocien (Mex) Vol 11, No. 4: 282-287, 2006 The Migraine- Epilepsy Syndrome Arch Neurocien (Mex) Vol. 11, No. 4: 282-287, 2006 Artículo de revisión ©INNN, 2006 de caso The migraine-epilepsy syndrome Enrique Otero Siliceo†, Fernando Zermeño EL SINDROME MIGRAÑA-EPILEPSIA represent a neural exitation. Since that the glutamate has in important rol in both patologys depending of the part of the brain more affected the symptoms might RESUMEN vary from visual to abdominal phemomena. La migraña y la epilepsia tienen varios puntos en común Key words: migraine epilepsy, EEG abnormalities, sintomática clínica y genéticamente lo que ha sido glutamate, diagnosis. postulado por más de cien años. El fenómeno referido como migraña-epilepsia sugiere que exista una he first steps of a practical, approach by patofisiología común. El síndrome de migraña o physicians in recognizing and treating neuro- epilepsia tiene fenómenos comunes de dolor adominal T logic diseases are to recognithat there are jaqueca anormalidades del EE y respuesta a droga various overlaps between migraine and epilepsy. antiepilépticas. En ocasiones el paciente puede tener Epileptic seizures and classic migraine episodes may un ataque migrañoso o una convulsión o en otras occur in the same patient. Migraine and epilepsy share ambas. La comorbilidad puede explicarse por estados several genetic, clinical, evolutive and neurophysio- de hiperrexcitabilidad neural. Alteraciones electroen- logic features. A relationship between epilepsy and cefalográficas son comunes en estos estados. En migraine has been postulated for over a hundred years apariencia el glutamato tiene un papel importante tanto and the syndrome of Migraine-Epilepsy illustrates this en la migraña como en la epilepsia.
    [Show full text]
  • Migraine Triggered Seizures and Epilepsy Triggered Headache and Migraine Attacks: a Need for Re-Assessment
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central J Headache Pain (2011) 12:287–288 DOI 10.1007/s10194-011-0344-2 COMMENTARY Migraine triggered seizures and epilepsy triggered headache and migraine attacks: a need for re-assessment Paul T. G. Davies • C. P. Panayiotopoulos Received: 5 April 2011 / Accepted: 8 April 2011 / Published online: 24 April 2011 Ó The Author(s) 2011. This article is published with open access at Springerlink.com In this issue of the Journal, Belcastro and associates review Migralepsy terminology and classification issues for migralepsy, hem- icrania epileptica, post-ictal and ictal headache [1]. They According to the ICHD-II 1.5.5, ‘‘migraine-triggered sei- raise key points such as ictal headache and visual seizures zure (sometimes referred to as migralepsy)’’ denotes an are often misdiagnosed as migraine, ‘‘migralepsy’’ is unli- epileptic seizure that occurs ‘‘during or within one hour kely to exist and an ‘‘epilepsy-migraine sequence’’ is much after a migraine aura’’ [3]. However, the evidence of this more common and well documented than the dominant ‘‘migraine-seizure’’ sequence is weak and the proposed view of a ‘‘migraine-epilepsy sequence’’. Their relevant criterion of 1 h gap between the end of the ‘‘aura’’ and the proposals need appropriate attention by the committee of start of an epileptic seizure is entirely arbitrary the international classification of headache disorders Migralepsy is an old term derived from migra(ine) and (ICHD) as well as the physicians in their clinical practice (epi)lepsy, coined by Dr Douglas Davidson, but mainly because of the consequences that misdiagnosis may have on attributed to Lennox and Lennox, which we quote, ‘‘a patients.
    [Show full text]
  • Myoclonic Status Epilepticus in Juvenile Myoclonic Epilepsy
    Original article Epileptic Disord 2009; 11 (4): 309-14 Myoclonic status epilepticus in juvenile myoclonic epilepsy Julia Larch, Iris Unterberger, Gerhard Bauer, Johannes Reichsoellner, Giorgi Kuchukhidze, Eugen Trinka Department of Neurology, Medical University of Innsbruck, Austria Received April 9, 2009; Accepted November 18, 2009 ABSTRACT – Background. Myoclonic status epilepticus (MSE) is rarely found in juvenile myoclonic epilepsy (JME) and its clinical features are not well described. We aimed to analyze MSE incidence, precipitating factors and clini- cal course by studying patients with JME from a large outpatient epilepsy clinic. Methods. We retrospectively screened all patients with JME treated at the Department of Neurology, Medical University of Innsbruck, Austria between 1970 and 2007 for a history of MSE. We analyzed age, sex, age at seizure onset, seizure types, EEG, MRI/CT findings and response to antiepileptic drugs. Results. Seven patients (five women, two men; median age at time of MSE 31 years; range 17-73) with MSE out of a total of 247 patients with JME were identi- fied. The median follow-up time was seven years (range 0-35), the incidence was 3.2/1,000 patient years. Median duration of epilepsy before MSE was 26 years (range 10-58). We identified three subtypes: 1) MSE with myoclonic seizures only in two patients, 2) MSE with generalized tonic clonic seizures in three, and 3) generalized tonic clonic seizures with myoclonic absence status in two patients. All patients responded promptly to benzodiazepines. One patient had repeated episodes of MSE. Precipitating events were identified in all but one patient. Drug withdrawal was identified in four patients, one of whom had additional sleep deprivation and alcohol intake.
    [Show full text]
  • Emergency Department Management of Neuroleptic Malignant Syndrome
    The Journal of Emergency Medicine, Vol. -, No. -, pp. 1–4, 2016 Ó 2016 Elsevier Inc. All rights reserved. 0736-4679/$ - see front matter http://dx.doi.org/10.1016/j.jemermed.2015.10.042 Selected Topics: Psychiatric Emergencies PSYCHIATRIC EMERGENCIES FOR CLINICIANS: EMERGENCY DEPARTMENT MANAGEMENT OF NEUROLEPTIC MALIGNANT SYNDROME Michael P. Wilson, MD, PHD,*† Gary M. Vilke, MD,*† Stephen R. Hayden, MD,* and Kimberly Nordstrom, MD, JD‡§ *University of California at San Diego Medical Center, San Diego, California, †Department of Emergency Medicine Behavioral Emergencies Research (DEMBER) Laboratory, University of California San Diego, San Diego, California, ‡Denver Health Medical Center, Department of Behavioral Health, Psychiatric Emergency Service, Denver, Colorado, and §University of Colorado Denver, School of Medicine, Aurora, Colorado Reprint Address: Michael P. Wilson, MD, PHD, Department of Emergency Medicine, University of California at San Diego Medical Center, 200 West Arbor Drive, Mail Code #8676, San Diego, CA, 92103 , Keywords—altered mental status; neuroleptic malig- What Do You Think is Going on with This Patient? nant syndrome; dystonia; catatonia; rigidity The clinical presentation suggests neuroleptic malignant syndrome (NMS). Although first described more than 50 years ago, the diagnosis of NMS is primarily CLINICAL SCENARIO clinical (1). A 25-year-old man presents with a recent diagnosis of schizophrenia. He was discharged 1 week earlier from What Key Findings Lead to the Diagnosis? an inpatient psychiatric unit. His mother states that he has been acting ‘‘differently’’ for the past 2 days. He Clues to an NMS diagnosis include a recent diagnosis of a has not been ‘‘making any sense,’’ has felt warm to the psychotic disorder and inpatient psychiatric hospitaliza- touch, and today has been stiff and moving rigidly like tion.
    [Show full text]
  • ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions
    ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions N Specchio1, EC Wirrell2*, IE Scheffer3, R Nabbout4, K Riney5, P Samia6, SM Zuberi7, JM Wilmshurst8, E Yozawitz9, R Pressler10, E Hirsch11, S Wiebe12, JH Cross13, P Tinuper14, S Auvin15 1. Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesu’ Children’s Hospital, IRCCS, Member of European Reference Network EpiCARE, Rome, Italy 2. Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester MN, USA. 3. University of Melbourne, Austin Health and Royal Children’s Hospital, Florey Institute, Murdoch Children’s Research Institute, Melbourne, Australia. 4. Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker–Enfants Malades Hospital, APHP, Member of European Reference Network EpiCARE, Institut Imagine, INSERM, UMR 1163, Université de Paris, Paris, France. 5. Neurosciences Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia. Faculty of Medicine, University of Queensland, Queensland, Australia. 6. Department of Paediatrics and Child Health, Aga Khan University, East Africa. 7. Paediatric Neurosciences Research Group, Royal Hospital for Children & Institute of Health & Wellbeing, University of Glasgow, Member of European Refence Network EpiCARE, Glasgow, UK. 8. Department of Paediatric Neurology, Red Cross War Memorial Children’s Hospital, Neuroscience Institute, University of Cape Town, South Africa. 9. Isabelle Rapin Division of Child Neurology of the Saul R Korey Department of Neurology, Montefiore Medical Center, Bronx, NY USA. 10. Programme of Developmental Neurosciences, UCL NIHR BRC Great Ormond Street Institute of Child Health, Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children, London, UK 11.
    [Show full text]
  • Lafora Disease Masquerading As Hepatic Dysfunction
    Thomas Jefferson University Jefferson Digital Commons Abington Jefferson Health Papers Abington Jefferson Health 8-24-2018 Lafora Disease Masquerading as Hepatic Dysfunction Faisal Inayat Allama Iqbal Medical College Waqas Ullah Abington Jefferson Health Hanan T. Lodhi University of Nebraska at Omaha Zarak H. Khan St. Mary Mercy Hospital Livonia Ghulam Ilyas SUNY Downstate Medical Center Follow this and additional works at: https://jdc.jefferson.edu/abingtonfp See next page for additional authors Part of the Gastroenterology Commons, and the Medical Genetics Commons Let us know how access to this document benefits ouy Recommended Citation Inayat, Faisal; Ullah, Waqas; Lodhi, Hanan T.; Khan, Zarak H.; Ilyas, Ghulam; Ali, Nouman Safdar; and Abdullah, Hafez Mohammad A., "Lafora Disease Masquerading as Hepatic Dysfunction" (2018). Abington Jefferson Health Papers. Paper 7. https://jdc.jefferson.edu/abingtonfp/7 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Abington Jefferson Health Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Authors Faisal Inayat, Waqas Ullah, Hanan T. Lodhi, Zarak H. Khan, Ghulam Ilyas, Nouman Safdar Ali, and Hafez Mohammad A.
    [Show full text]
  • RLS), a Clinical Diagnosis
    Liza Ashbrook, MD February 10, 2017 Recent Advances in Neurology Patient 1 This 70-year-old man has restless leg syndrome (RLS), a clinical diagnosis. RLS affects 5-10% of the adult population of European ancestry, though likely only 2-3% come to clinical attention. The cause of RLS is not clear but it is associated with low central iron stores. This is supported by evidence from autopsy studies, CSF analysis, gradient echo MRI and transcranial ultrasound. A family history of RLS is reported in 63-92% of individuals suggesting a strong genetic component as well. RLS is typically separated into intermittent symptoms, defined by fewer than twice/week over a year and chronic symptoms. When symptoms are only bothersome intermittently, such as a long plane flight, medications such as carbidopa/levodopa 25/100 can be very effective, however use more than twice weekly can lead to augmentation. Benzodiazepines and hypnotics are also recommended only for as needed use. Periodic limb movements (PLMs) occur in up to 80% of patients with RLS and are diagnosed by polysomnography. These are stereotyped kicking movements and patients are usually unaware of their presence though bed partners may complain. A small subset of those with PLMs are thought to have periodic leg movement disorder (PLMD), defined by PLMs causing either night time or daytime impairment. Other causes of insomnia and hypersomnia must be ruled out and those with RLS cannot have a diagnosis of PLMD. PLMs are of unclear clinical significance and may be a part of normal aging or an epiphenomenon. RLS and PLMs are commonly confused.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • Download Download
    Ziprasidone Associated Neuroleptic KANSAS JOURNAL of MEDICINE Malignant Syndrome Jeffrey D. Bell, M.D.1, Chancen Hall, D.O.2, Justin Sandall, D.O.2 1Beaver Medical Group, Redland, CA NMS, serotonin syndrome (SS), non-convulsive status epilepticus, 2University of Kansas School of Medicine-Wichita, Wichita, KS or other central nervous system (CNS) pathology. Blood, urine, and Department of Anesthesiology sputum cultures were obtained, and she was considered for a lumbar Received Oct. 7, 2019; Accepted for publication Dec. 21, 2020; Published online March 19, 2021 puncture to evaluate for meningitis. In addition, medical records were https://doi.org/10.17161/kjm.vol1411970 obtained from the outside facility and showed she had been receiving INTRODUCTION increasing doses of ziprasidone along with haloperidol, lithium, dulox- Neuroleptic malignant syndrome (NMS) is a severe and potentially etine, oxybutynin, and baclofen. lethal disorder due to an adverse reaction to dopamine receptor antag- Once this information was received and in consultation with our 1 onism or the rapid withdrawal of dopaminergic medications. While neurology and psychiatry colleagues, the patient was treated for a pre- 1 2 incidence is estimated to be 0.02% generally and 0.2% among neu- sumptive diagnosis of NMS with IV bromocriptine 10 mg every six roleptic users, NMS continues to be an unpredictable and potentially hours and a one-time dose of IV dantrolene 2.5 mg/kg, discontinuation life-threatening condition of which case reports continue to be a main of possible causative agents, a cooling blanket and antipyretics, and IV 3 source of information for clinicians. fluids. Despite the advent of second-generation antipsychotics (SGA), SS, which presents with dysautonomia and hyperreflexia in the NMS continues to be a rare yet severe adverse reaction to neurolep- setting of serotonergic medications, was considered for this patient, 4 tics.
    [Show full text]
  • A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
    The New England Journal of Medicine A COMPARISON OF FOUR TREATMENTS FOR GENERALIZED CONVULSIVE STATUS EPILEPTICUS DAVID M. TREIMAN, M.D., PATTI D. MEYERS, M.P.A., NANCY Y. WALTON, PH.D., JOSEPH F. COLLINS, SC.D., CINDY COLLING, R.PH., M.S., A. JAMES ROWAN, M.D., ADRIAN HANDFORTH, M.D., EDWARD FAUGHT, M.D., VINCENT P. CALABRESE, M.D., BASIM M. UTHMAN, M.D., R. EUGENE RAMSAY, M.D., AND MEENAL B. MAMDANI, M.D., FOR THE VETERANS AFFAIRS STATUS EPILEPTICUS COOPERATIVE STUDY GROUP* ABSTRACT TATUS epilepticus is a life-threatening emer- Background and Methods Although generalized gency that affects 65,0001 to 150,0002 peo- convulsive status epilepticus is a life-threatening ple in the United States each year. General- emergency, the best initial drug treatment is uncer- ized convulsive status epilepticus is the most tain. We conducted a five-year randomized, double- Scommon and most dangerous type. blind, multicenter trial of four intravenous regimens: Phenobarbital,3-5 phenytoin,6-14 diazepam plus phen- diazepam (0.15 mg per kilogram of body weight) fol- ytoin,15,16 and lorazepam17-28 have been advocated for lowed by phenytoin (18 mg per kilogram), lorazepam the initial treatment of generalized convulsive status (0.1 mg per kilogram), phenobarbital (15 mg per kil- epilepticus, and each is used by a substantial number ogram), and phenytoin (18 mg per kilogram). Pa- 3 tients were classified as having either overt general- of physicians. There are few data from controlled ized status epilepticus (defined as easily visible trials, however, to document the efficacy of these generalized convulsions) or subtle status epilepticus treatments, and they have not been directly com- (indicated by coma and ictal discharges on the elec- pared.
    [Show full text]
  • Unusual Course of Lafora Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Groningen University of Groningen Unusual course of Lafora disease Zutt, Rodi; Drost, Gea; Vos, Yvonne; Elting, J.W.J.; Miedema, I.; tijssen, m.a.; Brouwer, Oebele; de Jong, Bauke M Published in: epilepsia open DOI: 10.1002/epi4.12009 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zutt, R., Drost, G., Vos, Y., Elting, J. W. J., Miedema, I., tijssen, M. A., ... de Jong, B. M. (2016). Unusual course of Lafora disease. epilepsia open, 1(3-4), 136-139. https://doi.org/10.1002/epi4.12009 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
    [Show full text]